Recurrent Vulvovaginal Candidiasis Therapeutics
1. Vivjoa patent expiration
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of re...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236962 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(5 years from now) | |
| US9840492 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(10 years from now) | |
| US10414751 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11247981 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
May, 2033
(7 years from now) | |
| US8754227 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 27 April, 2031
Market Authorisation Date: 26 April, 2022
Dosage: CAPSULE
More Information on Dosage
VIVJOA family patents
